Since its first report in December 2019 from China, the COVID-19 pandemic caused by the beta-coronavirus SARS-CoV-2 has spread at an alarming pace infecting about 5.59 million, and claiming the lives of more than 0.35 million individuals across the globe. The lack of a clinically approved vaccine or drug remains the biggest bottleneck in combating the pandemic. Drug repurposing can expedite the process of drug development by identifying known drugs which are effective against SARS-CoV-2. The SARS-CoV-2 main protease is a promising drug target due to its indispensable role in viral multiplication inside the host. In the present study an E-pharmacophore hypothesis was generated using a crystal structure of the viral protease in complex with an imidazole carbaximide inhibitor. Drugs available in the superDRUG2 database were used to identify candidate drugs for repurposing. The hits obtained from the pharmacophore based screening were further screened using a structure based approach involving molecular docking at different precisions. The binding energies of the most promising compounds were estimated using MM-GBSA. The stability of the interactions between the selected drugs and the target were further explored using molecular dynamics simulation at 100 ns. The results showed that the drugs Binifibrate and Bamifylline bind strongly to the enzyme active site and hence they can be repurposed against SARS-CoV-2. However, U.S Food and Drug Administration have withdrawn Binifibrate from the market as it was having some adverse health effects on patients. Communicated by Ramaswamy H. Sarma
29 September 2011 in Interdisciplinary Sciences: Computational Life Sciences
Inhibition of acetylcholinesterase (AChE) is a promising treatment strategy for Alzheimer's disease (AD). Oxidative stress, inflammation and accumulation of metal ions at sites of neurodegeneration have been observed in association with AD. Flavonoids are well known for their action against inflammation and oxidative stress. Hence, they can be used for treating diseases such as AD, cancer, atherosclerosis and Parkinson's disease. Flavonols such as quercetin, myricetin, galangin, fisetin and kaempferol have been reported as inhibitors of AChE. In the present work, the enzyme inhibitory properties of morin, a flavonol, has been tested against AChE. The binding pattern of morin and 12 other flavonols at the active site of human AChE has been analyzed using molecular modeling and docking methods. In order to enhance the binding affinity of AChE for morin, in silico structural modification of the compound was carried out. The structural elements responsible for its biological functions were retained during the modification. Some of the derivatives possessed better binding energies than morin and hence they could be used as drug lead compound for the treatment of AD.
Fungal laccases are involved in a variety of physiological functions such as delignification, morphogenesis and parasitism. In addition to these functions, we suggest that fungal laccases are involved in defense mechanisms. When the laccase secreting Trichoderma viride was grown in the presence of a range of microorganisms including bacteria and fungi, laccase secretion was enhanced in response to antagonistic organisms alone. In addition, growth of antagonistic microbes was restricted by the secreting fungi. Besides, our study for the first time shows the inability of the secreting fungi (T.viride) to compete with antagonistic organism when laccase activity is inhibited, further emphasizing its involvement in rendering a survival advantage to the secreting organism. When laccase inhibitor was added to the media, the zone of inhibition exerted by the antagonist organism was more pronounced and consequently growth of T. viride was significantly restricted. Based on these observations we accentuate that, laccase plays an important role in defense mechanism and provides endurance to the organism when encountered with an antagonistic organism in its surrounding.
Inhibiting PLA2 activity should, in theory, be an effective approach to control the inflammation. Several naturally occurring polyphenolic compounds have been reported as inhibitors of PLA2. Among the naturally occurring polyphenols, catechol (1,2‐dihydroxybenzene) possesses anti‐inflammatory activity. Catechol can inhibit cyclooxygenase and lipo‐oxygenase. By means of enzyme kinetic study, it was revealed that catechol can inhibit PLA2 also. Crystal structure showed that catechol binds to PLA2 at the opening of the active site cleft. This might stop the entry of substrate into the active site. Hence, catechol can be used as a lead compound for the development of novel anti‐inflammatory drugs with PLA2 as the target.